|
|||||
|
|
Epstein‐Barr virus infection induces miR‐21 in terminally differentiated malignant B cells |
|
| Authors: | Eleni Anastasiadou Neha Garg Rachele Bigi Shivangi Yadav Antonio Francesco Campese Caterina Lapenta Massimo Spada Laura Cuomo Annalisa Botta Filippo Belardelli Luigi Frati Elisabetta Ferretti Pankaj Trivedi |
| Affiliation: | 1. Department of Experimental Medicine, La Sapienza University, Rome, Italy;2. Department of Molecular Medicine, La Sapienza University, Rome, Italy;3. Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Rome, Italy;4. Department of Clinical Pathology, San Filippo Neri Hospital, Rome, Italy;5. Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy |
| Abstract: | The association of Epstein‐Barr virus (EBV) with plasmacytoid malignancies is now well established but how the virus influences microRNA expression in such cells is not known. We have used multiple myeloma (MM) cell lines to address this issue and find that an oncomiR, miR‐21 is induced after in vitro EBV infection. The PU.1 binding site in miR‐21 promoter was essential for its activation by the virus. In accordance with its noted oncogenic functions, miR‐21 induction in EBV infected MM cells caused downregulation of p21 and an increase in cyclin D3 expression. EBV infected MM cells were highly tumorigenic in SCID mice. Given the importance of miR‐21 in plasmacytoid malignancies, our findings that EBV could further exacerbate the disease by inducing miR‐21 has interesting implications both in terms of diagnosis and future miR based therapeutical approaches for the virus associated plasmacytoid tumors. |
| Keywords: | miR‐21 EBV plasma cells multiple myeloma |